Abbott study shows promise for DBS therapy for treatment-resistant depression

This study is a strong example of how our therapies can contribute to the innovation taking place within the broad field of neuroscience. We applaud the researchers who led this study and look forward to future advancements to support the care of people suffering from chronic, treatment-resistant depression,” Abbott neuromod division medical director Dr. Allen Burton said in a prepared statement. Abbott said that currently its DBS system is only indicated for treating essential tremor and Parkinson’s disease. Earlier this month, Abbott closed its $5.3 billion buy of diagnostics giant Alere (NYSE:ALR), ending an acquisition process the company has been engaged in since last Feb. See the best minds in medtech live at DeviceTalks West, Dec. 11–12 in Orange County, Calif. The post Abbott study shows promise for DBS therapy for treatment-resistant depression appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Tags: Clinical Trials Neuromodulation/Neurostimulation Abbott Source Type: news